Alfa M, Harding G, Ronald A, Light R, Macfarlane N, Olson N, Degagne P, Kasdorf K, Simor A, Macdonald K, Louie L
Departments of Microbiology, and Infectious Diseases, St Boniface General Hospital, Winnipeg, Manitoba;
Can J Infect Dis. 1999 Jul;10(4):287-94. doi: 10.1155/1999/102891.
To monitor prospectively patients with Clostridium difficile-associated diarrhea (CAD) in a six hundred bed tertiary care hospital to determine which factors influenced the recurrence of the diarrhea.
A prospective, nonrandomized study. After an initial diagnosis of CAD, patients were interviewed, and each week stool samples and environmental samples were monitored for the presence of toxigenic C difficile for as long as the patients remained in hospital. The relationship of concurrent antibiotics, prolonged fecal excretion of organism or toxin, and environmental contamination was assessed.
Over a two-and-a-half year period, 75 consecutive patients with CAD were selected and those who gave their written informed consent were enrolled. A control group to evaluate environmental contamination consisted of 75 patients with diarrhea not associated with C difficile.
Of the 75 CAD patients, 11 (14.7%) had a recurrence of their diarrhea. Diarrhea recurrence was associated with an increased rate of prolonged excretion of toxigenic organism and/or C difficile toxin(s) (nine of 11 [81.8%] compared with nine of 64 [14.1%]; P≤0.0001; relative risk 14.25; 95% CI 3.383 to 60.023). The risk of diarrhea recurrence was not related to a specific antibiotic but to concurrent therapy. Treatment within 30 days of initial CAD-specific treatment with an antibiotic other than metronidazole or vancomycin occurred significantly more frequently in patients with recurrence of diarrhea compared with those who did not have a recurrence (eight of 11 [72.7%] compared with 22 of 64 [34.4%], P=0.022; relative risk 4; 95% CI 1.153 to 13.881). The environmental contamination rate for toxigenic C difficile in week one in the rooms of patients with diarrhea not caused by C difficile was low (two of 75 [2.6%]) compared with week one data for patients with CAD (14 of 75 [18.7%], P=0.002; relative risk 1.922; 95% CI 1.479 to 2.498). The most frequent site contaminated was the bedpan sprayer (eight of 14 [57.1%]). Pulsed field gel electrophoresis analysis of stool and environmental toxigenic isolates indicated that there was not a single endemic strain of C difficile.
This study indicates that the recurrence of diarrhea may be related to concurrent 'other' antibiotics. Although data indicated that there was a correlation between diarrhea recurrence and prolonged fecal excretion of toxin, further studies are required to clarify the clinical significance.
在一家拥有600张床位的三级护理医院中,对艰难梭菌相关性腹泻(CAD)患者进行前瞻性监测,以确定哪些因素会影响腹泻的复发。
一项前瞻性、非随机研究。在初步诊断为CAD后,对患者进行访谈,并且只要患者住院,每周都对粪便样本和环境样本进行监测,以检测产毒艰难梭菌的存在。评估同时使用抗生素、机体或毒素的粪便排泄延长以及环境污染之间的关系。
在两年半的时间里,连续选择了75例CAD患者,那些给予书面知情同意的患者被纳入研究。一个用于评估环境污染的对照组由75例与艰难梭菌无关的腹泻患者组成。
75例CAD患者中,11例(14.7%)腹泻复发。腹泻复发与产毒机体和/或艰难梭菌毒素排泄延长的发生率增加相关(11例中的9例[81.8%],相比之下64例中的9例[14.1%];P≤0.0001;相对风险14.25;95%置信区间3.383至60.023)。腹泻复发的风险与特定抗生素无关,而是与同时进行的治疗有关。与未复发的患者相比,在初次CAD特异性治疗后30天内使用甲硝唑或万古霉素以外的抗生素进行治疗的腹泻复发患者明显更常见(11例中的8例[72.7%],相比之下64例中的22例[34.4%],P = 0.022;相对风险4;95%置信区间1.153至13.881)。在非艰难梭菌引起的腹泻患者房间中,第1周产毒艰难梭菌的环境污染率较低(75例中的2例[2.6%]),与CAD患者第1周的数据(75例中的14例[18.7%])相比(P = 0.002;相对风险1.922;95%置信区间1.479至2.498)。污染最频繁的部位是便盆喷雾器(14例中的8例[57.1%])。对粪便和环境中产毒分离株的脉冲场凝胶电泳分析表明,不存在单一的艰难梭菌流行菌株。
本研究表明腹泻复发可能与同时使用“其他”抗生素有关。尽管数据表明腹泻复发与毒素的粪便排泄延长之间存在相关性,但需要进一步研究以阐明其临床意义。